Abbott Laboratories vs. Sarepta Therapeutics,, Inc. Common Stock
ABT
Abbott Laboratories
$111.25 -0.02%
VS SRPTSarepta Therapeutics,, Inc. Common Stock
$18.10 -1.74%
Abbott Laboratories (ABT) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| ABT | SRPT | |
|---|---|---|
| Market Cap | $191.92 billion | $1.94 billion |
| Revenue (TTM) | $46.59 billion | $1.97 billion |
| Net Income (TTM) | $5.42 billion | $-136,725,000 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | SRPT | |
|---|---|---|
| P/E Ratio | 36.00 | — |
| Price / Book | 3.71 | 1.27 |
| Price / Sales | 4.12 | 0.98 |
SRPT leads on 2 of 2 valuation factors.
Profitability
| ABT | SRPT | |
|---|---|---|
| Net Margin | 11.65% | -6.93% |
| Return on Equity | 10.48% | -8.95% |
ABT leads on 2 of 2 profitability factors.
Dividend
| ABT | SRPT | |
|---|---|---|
| Dividend Yield | 2.27% | — |
| Payout Ratio | 81.55 | — |
ABT and SRPT split the dividend factors evenly.
Risk & Sentiment
| ABT | SRPT | |
|---|---|---|
| Short Interest | 0.57% | 9.38% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, SRPT overview, SRPT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.